TriSalus Life Sciences, Inc.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $45.2M
- Net income
- -$39.2M
- Total assets
- $35.3M
- Market cap
- $194.7M
- Gross margin
- 84.6%
- Operating margin
- -59.7%
- Net margin
- -86.9%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $45.2M
- Cost of revenue
- $7.0M
- Gross profit
- $38.2M
- Operating expenses
- $65.1M
- Operating income
- -$26.9M
- Income tax
- $7.0K
- Net income
- -$39.2M
- EPS (basic)
- $-1.84
- EPS (diluted)
- $-1.84
Balance sheet
- Total assets
- $35.3M
- Current assets
- $32.2M
- Total liabilities
- $69.2M
- Current liabilities
- $11.5M
- Shareholders’ equity
- -$33.9M
Cash flow
- Operating cash flow
- -$18.0M
- Investing cash flow
- -$838.0K
- Financing cash flow
- $30.8M
- Net cash flow
- $11.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $194.7M
- EPS (diluted)
- $-1.84
- Shares outstanding
- 60.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 11, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.2M in FY2025.
- Revenue grew 144% from FY2023 to FY2025.
- Gross margin of 84.6%, net margin -86.9%.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TriSalus Life Sciences, Inc..
Write a review
News about TriSalus Life Sciences, Inc.
News & sentiment via Polygon.io
